Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
SEC filings, financial facts, source resources, and Goglides workspace context for ABVC BioPharma, Inc..
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Aeries has turned fiscal 2026 adjusted EBITDA positive and sells an AI-enabled GCC model to private-equity and middle-market clients, but the latest filings also show going-concern doubt, Nasdaq delisting proceedings, FPA obligations and control weaknesses.
OpenABVC looks like a tiny biotech, a licensing company, a CDMO, and a Taiwan real-asset story in the same filing. The first proof gate is whether cash, controls, and partners can catch up to the size of the pipeline.
OpenAccenture has record Q2 bookings, $5.9 billion of FY2025 generative AI bookings, and elite cash conversion. The decision point is whether AI and managed services can outrun selective consulting demand, U.S. federal pressure, and the cost of reshaping an almost
OpenAECOM has record backlog, rising net service revenue, raised FY2026 earnings guidance, a shareholder-return machine, and a bold AI/advisory margin story. The pressure point is less glamorous: Q2 fiscal 2026 free cash flow was negative because collections and c
OpenTag facets appear after tag usage counts are rebuilt.